Subcutaneous T pellet implants have been available in the United States since 1972 and afford several advantages over other T formulations, including 100% patient compliance, avoidance of the peaks and troughs found with injectable treatments, lower risk of drug transfer from patient to others, and maintenance of a stably elevated serum T level. While T pellets are used to treat androgen deficiency, limited data exist regarding their pharmacokinetics and side effect profiles. Furthermore, the incidence of erythrocytosis and effects on lipid profiles is relatively unknown for T pellets.
Determining optimal dosing of T pellets can be challenging, as individual rates of T metabolism must be considered, and these likely reflect patient weight and body mass index (BMI), as well as volume of distribution and sex hormone binding globulin (SHBG) concentration. Thus, further evaluation of the pharmacokinetics of T pellets is merited in order to determine optimal dosing and to establish side effect profiles. In this study, researchers evaluate the pharmacokinetics of T pellets in a cohort of hypogonadal men, permitting an objective evaluation of serum T metabolism and leading to dosing parameters for these pellets. They also assess symptomatic benefits of T pellets as well as adverse events including erythrocytosis and impact on PSA levels.
They find that subcutaneous T pellets represent a safe, efficacious mode of TRT, and that the effects on serum hormone levels and hypogonadal symptoms of these pellets are a function of the number of pellets implanted and patient BMI. Men with BMI <25 achieve therapeutic TT levels with fewer than 10 pellets, whereas men with BMI ?25 require 10 or more pellets to achieve therapeutic TT levels, and most men demonstrate improvement in hypogonadal symptoms after pellet implantation. Regardless of the number of pellets implanted, roughly equal serum TT levels are observed at 100-120 days, indicating that re-implantation should be performed at this time. Furthermore, 320 multiple sequential implantations do not appear to affect TT decay kinetics, nor do pre-implantation TT levels. Finally, minimal effects on Hgb and Hct parameters, and no effects on PSA, particularly in men with CaP, were observed.
Pastuszak AW, Mittakanti H, Liu JS, Gomez LP, Lipshultz LI, Khera M. Pharmacokinetic Evaluation and Dosing of Subcutaneous Testosterone Pellets. J Androl. Pharmacokinetic Evaluation and Dosing of Subcutaneous Testosterone Pellets -- Pastuszak et al., 10.2164/jandrol.111.016295 -- Journal of Andrology
Introduction and Objective: Subcutaneous testosterone (T) pellets are a viable treatment modality for hypogonadism. Optimal dosing, frequency of reimplantation, and long-term safety of T pellets remain incompletely elucidated parameters.
Methods: A retrospective review of 273 patients treated for hypogonadism using subcutaneous T pellets was performed. Serum total T (TT), free T (FT), and estradiol (E) levels were analyzed as a function of time from implantation, number of pellets implanted (6-9 or 10-12), BMI (<25 or >/=25), number of implantations (up to 4 rounds, 501 insertions) and pre-implantation T levels (<300 or >/=300ng/dL). T decay was determined using linear regression and TT levels at day 1 post-implantation and the time for TT levels to reach 300ng/dL extrapolated for all variables.
Results: Mean(SD) subject age was 56±12.6 years. Baseline TT was 328±202 ng/dL, FT 9.49±27.8 pg/mL and E 25.1±17.3 pg/mL. Extrapolated TT and FT peaks were lower in men receiving 6-9 pellets than 10-12, though decay rates differed insignificantly. E levels rose significantly in men receiving 10-12, but not 6-9 pellets. Men with BMI >/=25 attained lower TT peaks with slower decay than men with BMI <25 receiving 10-12 pellets, though 300ng/dL TT levels were reached at ~100 days in both groups. No differences were seen in decay rates for men with multiple implant rounds, and no differences in T peaks or decay rates were seen in men with pre-implant T <300 or >/=300ng/dL. One patient developed erythrocytosis and no PSA recurrences were observed in men with prostate cancer treated with T pellets.
Conclusions: Men with BMI <25 should receive fewer pellets and re-implantation for all men should occur 100-120 days after prior implantation. Men receiving 10-12 pellets have higher E levels, potentially reflecting increased aromatization of testosterone. Reimplantation and pre-implantation TT levels do not affect pellet decay kinetics.
Determining optimal dosing of T pellets can be challenging, as individual rates of T metabolism must be considered, and these likely reflect patient weight and body mass index (BMI), as well as volume of distribution and sex hormone binding globulin (SHBG) concentration. Thus, further evaluation of the pharmacokinetics of T pellets is merited in order to determine optimal dosing and to establish side effect profiles. In this study, researchers evaluate the pharmacokinetics of T pellets in a cohort of hypogonadal men, permitting an objective evaluation of serum T metabolism and leading to dosing parameters for these pellets. They also assess symptomatic benefits of T pellets as well as adverse events including erythrocytosis and impact on PSA levels.
They find that subcutaneous T pellets represent a safe, efficacious mode of TRT, and that the effects on serum hormone levels and hypogonadal symptoms of these pellets are a function of the number of pellets implanted and patient BMI. Men with BMI <25 achieve therapeutic TT levels with fewer than 10 pellets, whereas men with BMI ?25 require 10 or more pellets to achieve therapeutic TT levels, and most men demonstrate improvement in hypogonadal symptoms after pellet implantation. Regardless of the number of pellets implanted, roughly equal serum TT levels are observed at 100-120 days, indicating that re-implantation should be performed at this time. Furthermore, 320 multiple sequential implantations do not appear to affect TT decay kinetics, nor do pre-implantation TT levels. Finally, minimal effects on Hgb and Hct parameters, and no effects on PSA, particularly in men with CaP, were observed.
Pastuszak AW, Mittakanti H, Liu JS, Gomez LP, Lipshultz LI, Khera M. Pharmacokinetic Evaluation and Dosing of Subcutaneous Testosterone Pellets. J Androl. Pharmacokinetic Evaluation and Dosing of Subcutaneous Testosterone Pellets -- Pastuszak et al., 10.2164/jandrol.111.016295 -- Journal of Andrology
Introduction and Objective: Subcutaneous testosterone (T) pellets are a viable treatment modality for hypogonadism. Optimal dosing, frequency of reimplantation, and long-term safety of T pellets remain incompletely elucidated parameters.
Methods: A retrospective review of 273 patients treated for hypogonadism using subcutaneous T pellets was performed. Serum total T (TT), free T (FT), and estradiol (E) levels were analyzed as a function of time from implantation, number of pellets implanted (6-9 or 10-12), BMI (<25 or >/=25), number of implantations (up to 4 rounds, 501 insertions) and pre-implantation T levels (<300 or >/=300ng/dL). T decay was determined using linear regression and TT levels at day 1 post-implantation and the time for TT levels to reach 300ng/dL extrapolated for all variables.
Results: Mean(SD) subject age was 56±12.6 years. Baseline TT was 328±202 ng/dL, FT 9.49±27.8 pg/mL and E 25.1±17.3 pg/mL. Extrapolated TT and FT peaks were lower in men receiving 6-9 pellets than 10-12, though decay rates differed insignificantly. E levels rose significantly in men receiving 10-12, but not 6-9 pellets. Men with BMI >/=25 attained lower TT peaks with slower decay than men with BMI <25 receiving 10-12 pellets, though 300ng/dL TT levels were reached at ~100 days in both groups. No differences were seen in decay rates for men with multiple implant rounds, and no differences in T peaks or decay rates were seen in men with pre-implant T <300 or >/=300ng/dL. One patient developed erythrocytosis and no PSA recurrences were observed in men with prostate cancer treated with T pellets.
Conclusions: Men with BMI <25 should receive fewer pellets and re-implantation for all men should occur 100-120 days after prior implantation. Men receiving 10-12 pellets have higher E levels, potentially reflecting increased aromatization of testosterone. Reimplantation and pre-implantation TT levels do not affect pellet decay kinetics.
Attachments
Last edited: